A Slate of 10 Humira Biosimilars to Hit US Market in 2023

Abbvie’s 20-year competition-free history is set to end in 2023, with as many as 10 biosimilars for its notoriously expensive Humira headed to the US this year. The first, Amgen’s Amjevita, hits the market this month, with several others to follow as the US Centers for Medicare and Medicaid Services (CMS) preparing to begin drug price regulations that were partially inspired by the high cost of Humira.

According to Tony Hagen, “The question now is, how much and how quickly can biosimilar price competition make a difference in the cost of this biologic? Never in the short history of U.S. biosimilars have so many biosimilars for one reference product entered the market at one time. Neither AbbVie nor biosimilar makers have disclosed their product price expectations for 2023, but AbbVie executives recently noted that four years of biosimilar competition in the European Union have left Humira with just a 30% share of its former market.”

To read more, click here.

(Source: Managed Healthcare Executive, January 11^th, 2023)